Title of article :
Monetary Value of Quality-Adjusted Life Years (QALY) among Patients with Cardiovascular Disease: a Willingness to Pay Study (WTP)
Author/Authors :
Moradi, Najmeh School of Pharmacy - Shahid Beheshti University of medical sciences, Tehran, Iran , Rashidian, Arash School of Public Health - Tehran University of Medical Sciences, Tehran, Iran , Rasekh, Hamid Reza School of Pharmacy - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Olyaeemanesh, Alireza Health Economics Department - National Institute for Health Research - Tehran University of Medical Sciences, Tehran, Iran , Foroughi, Mahnoosh cardiovascular research center - Shahid Beheshti University of medical sciences, Tehran, Iran , Mohammadi, Teymoor Economics Faculty - Allameh Tabatabaei University, Tehran Iran
Abstract :
The aim of this study was to estimate the monetary value of a QALY among patients with
heart disease and to identify its determinants. A cross-sectional survey was conducted through
face-to-face interview on 196 patients with cardiovascular disease from two heart hospitals in
Tehran, Iran, to estimate the value of QALY using disaggregated and aggregated approaches.
The EuroQol-5 Dimension (EQ-5D) questionnaire, Visual Analogue Scale (VAS), Time Trade-
Off (TTO) and contingent valuation WTP techniques were employed, first to elicit patients’
preferences and then, to estimate WTP for QALY. The association of patients’ characteristics
with WTP for QALY, was assessed through Heckman selection model. The Mean willingness
to pay per QALY, estimated by the disaggregated approach ranged from 2,799 to 3599 US
dollars. It is higher than the values, estimated from aggregated methods (USD 2,256 to 3,137).
However, in both approaches, the values were less than one Gross Domestic Product (GDP)
per capita of Iran.
Significant variables were: Current health state, education, age, marital status, number of
comorbidities, and household’s cost group. Our results challenge two major issues: the first, is
a policy challenge which concerns the WHO recommendation to use less than 3 GDP per capita
as a cost-effectiveness threshold value. The second, is an analytical challenge related to patients
with zero QALY gain. More scrutiny is suggested on the issue of how patients with full health
state valuation should be dealt with and what arbitrary value could be included in the estimation
value of QALY when the disaggregated approach used.
Keywords :
Cardiovascular diseases , Cost -Effectiveness threshold value , Contingent Valuation Method , Quality-Adjusted Life Year , Willingness To Pay
Journal title :
Astroparticle Physics